Novo Nordisk within touching distance of European obesity market as CHMP recommends approval
The EU Committee for Medicinal Products for Human Use has recommended that Novo Nordisk's obesity drug Wegovy be approved. The pharmaceutical company expects to launch the product in Europe in the second half of 2022.
BY CHRISTOPHER DUE KARLSSON, TRANSLATED BY CATHERINE BRETT AND DANIEL PEDERSEN
Novo Nordisk has come one step closer to getting its obesity drug Wegovy approved in Europe, as the CHMP has recommended is approval.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
.jpg)
Wegovy weight loss results "very encouraging," says Novo EVP
For subscribers
Raising ambitions at Novo Nordisk an obvious move, says CEO
For subscribers
